Fintech

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease

Prnewswire·March 26, 2026 at 11:30 AM

/PRNewswire/ --Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...

Original Source

Prnewswire — www.prnewswire.com

Related in Fintech

Wells Fargo virtual assistant aids over 1 billion transactions
PYMNTS
White House crypto czar joins science advisory committee
CoinDesk
David Sacks leaves crypto post for White House
The Block
Lawmakers Question Bank Regulators on Fintech Rules
PYMNTS

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease

Wells Fargo virtual assistant aids over 1 billion transactions

White House crypto czar joins science advisory committee

David Sacks leaves crypto post for White House

Lawmakers Question Bank Regulators on Fintech Rules